摘要
目的:系统评价替米沙坦对比氯沙坦治疗原发性高血压的疗效与安全性,以为临床提供循证参考。方法:计算机检索Cochrane图书馆、Medline、PubMed、EMBase、中国期刊全文数据库、中文科技期刊全文数据库、中国生物医学文献数据库,全面收集替米沙坦与氯沙坦治疗原发性高血压的随机对照试验(RCT),对符合纳入标准的文献进行质量评价,并运用Rev Man 5.0统计软件进行Meta分析。结果:共纳入11项RCT,合计1 907例患者。Meta分析结果显示,替米沙坦降低患者收缩压[MD=-3.37,95%CI(-4.99,-1.75),P<0.000]、舒张压[MD=-2.76,95%CI(-4.04,-1.49),P<0.000]及降压有效率[RR=1.14,95%CI(1.05,1.24),P=0.002]均显著优于氯沙坦,两组比较差异均有统计学意义;两组患者不良反应发生率比较差异无统计学意义[RR=0.91,95%CI=(0.74,1.12),P=0.38]。结论:替米沙坦治疗原发性高血压疗效优于氯沙坦,安全性相似。
OBJECTIVE： To systematically evaluate the efficacy and safety of telmisartan and losartan in the treatment of essen- tial hypertension, and to provide evidence-based reference for clinical use. METHODS： Retrieved from Cochrane library, Med- line, PubMed, EMBase, CNKI, VIP and CBM database by computer, randomized controlled trials （RCT） about telmisartan ver- sus losartan in the treatment of essential hypertension were collected. The methodological quality of the included studies was evaluat- ed and Meta-analysis was drawn by Rev Man 5.0 statistical sofetware. RESULTS： A total of 11 RCT were included, involving 1 907 pa- tients. The results of meta-analysis revealed that telmisartan was better than losartan in systolic blood pressure reduction [MD= -- 3.37, 95 % CI （ - 4.99, - 1.75）, P（0.000], diastolic blood pressure reduction [MD = - 2.76, 95 % CI （ - 4.04, - 1.49）, P（ 0.000] and therapeutic responses [RR= 1.14, 95 % CI （1.05, 1.24）, P= 0.002] ; there was statistical significance. There were no significant difference in ADR [RR = 0.91, 95 % CI （0.74, 1.12）, P= 0.38]. CONCLUSIONS： Telmisartan is more effective than losartan in the treatment of essential hypertension, and they have similar safety.
出处
《中国药房》
CAS
CSCD
2014年第32期3046-3048,共3页
China Pharmacy
